vps-33.1 Antibody

What is VPS-33.1 and why is it important in cellular biology?

VPS-33.1 (VPS33B) is a Sec1-Munc18 (SM) family protein that plays a critical role in membrane fusion events and intracellular transport. VPS33B forms a unique complex with VPS16B (VIPAS39/SPE-39), creating a bidirectional structure with two VPS33B molecules forming the cores of each lobe oriented in trans. This arrangement is unprecedented among SM proteins and likely contributes to its essential role in specific membrane fusion events. The protein is particularly important in endosomal maturation pathways, and mutations in VPS33B cause ARC syndrome in humans, characterized by neurogenic joint alterations, kidney and liver dysfunction, and neurodevelopmental abnormalities .

How do VPS33B antibodies contribute to understanding protein interactions?

VPS33B antibodies have been instrumental in elucidating the interactions between VPS33B and its binding partners. Through immunoprecipitation experiments, researchers have demonstrated that VPS33B directly interacts with VIPAS39/SPE-39, but not with other components of the HOPS (homotypic fusion and protein sorting) complex such as Vps11 or Vps18 in direct binding assays. Antibodies have helped reveal that pathogenic mutations in VPS33B can affect its interaction with VIPAS39/SPE-39 to varying degrees, while generally not disrupting integration into HOPS complexes. These antibodies have been crucial in mapping interaction domains and understanding how mutations in VPS33B lead to disease states .

What is the molecular structure of the VPS33B-VPS16B complex?

The VPS33B-VPS16B complex has been characterized as a high molecular weight complex of approximately 315 kDa as determined by SEC-multiangle light scattering (SEC-MALS). Quantitative immunoblotting revealed that this complex consists of two copies of VPS33B associated with three copies of VPS16B. Small-angle X-ray scattering and single-particle negative-staining transmission electron microscopy have shown that the complex forms a stable two-lobed structure. Individual copies of VPS33B form the cores of each lobe in a unique bidirectional (trans) configuration, which is unprecedented among SM proteins and likely essential for its specific function in membrane fusion events .

How should researchers design immunoprecipitation experiments with VPS-33.1 antibodies?

When designing immunoprecipitation experiments with VPS-33.1 antibodies, researchers should consider several factors:

• Control for specificity by including non-transfected cell extracts or irrelevant proteins such as transferrin receptor

• Consider using cross-linking agents such as DSP (dithiobis[succinimidyl propionate]) to stabilize potentially weak interactions

• Include positive controls with wild-type VPS33B and negative controls with known non-interacting proteins

• For co-immunoprecipitation of complexes, consider co-expression systems with tagged proteins (e.g., HA-tagged VPS33B and Myc-tagged interaction partners)

• Use appropriate lysis conditions that preserve protein-protein interactions

Research has shown that these approaches can successfully detect interactions between VPS33B and partners like VIPAS39/SPE-39, as well as components of the HOPS complex like Vps18 and Vps41 .

What are the key considerations for using VPS-33.1 antibodies in transport inhibition assays?

When using VPS-33.1 antibodies in transport inhibition assays, researchers should consider:

• Antibody concentration: Previous studies have shown >90% inhibition of transport with anti-Vps33p antibodies

• Specificity controls: Include pre-immune serum or irrelevant antibodies as negative controls

• Rescue experiments: Design complementary assays using cytosolic extracts from cells overexpressing VPS33B to restore transport in antibody-inhibited systems

• Membrane preparation: Carefully prepare donor and acceptor membranes (e.g., 125,000-g pellet for donor membranes containing proCPY and 15,000-g pellet for acceptor membranes enriched for vacuoles)

• Assay conditions: Standard conditions include donor membranes, acceptor membranes, ATP, an ATP regeneration system, and cytosol at appropriate concentrations

These considerations are important as demonstrated in cell-free assays where antibodies against Vps33p inhibited transport by >90%, and this inhibition could be reversed by cytosolic extracts from yeast cells overexpressing Vps33p .

How can researchers differentiate between effects on VPS33B-VIPAS39 binding versus HOPS complex formation?

To differentiate between effects on VPS33B-VIPAS39 binding versus HOPS complex formation, researchers should employ parallel experimental approaches:

• Direct binding assays: Use yeast two-hybrid (Y2H) analyses to assess direct binding between VPS33B and VIPAS39/SPE-39

• Co-immunoprecipitation assays: Test whether mutant forms of VPS33B can co-precipitate with VIPAS39/SPE-39

• HOPS complex integration: Separately examine co-precipitation of VPS33B with HOPS components like Vps18 and Vps41

• Cross-linking experiments: Use chemical cross-linking to stabilize potentially weaker interactions

• Structural analysis: When possible, employ structural approaches to define specific interaction domains

Research has shown that pathogenic mutations in VPS33B can have differential effects on binding partners. For instance, the ARC mutation L30P disrupts VPS33B-VIPAS39/SPE-39 binding, while the D234H mutation maintains this interaction. Importantly, both mutants still incorporate into HOPS complexes by co-immunoprecipitating with Vps18 and Vps41 .

How do VPS33B pathogenic mutations affect antibody epitope recognition?

Pathogenic mutations in VPS33B may affect antibody epitope recognition depending on the location of the mutation relative to the antibody binding site. Research suggests several considerations:

• Conformational changes: Mutations may alter protein folding even when they don't prevent complex formation, potentially masking or exposing epitopes

• Domain-specific effects: Mutations in the evolutionary conserved region (amino acids 221-260) of VPS33B might particularly affect certain domain-specific antibodies

• Cross-species recognition: Antibodies generated against human VPS33B may have differential recognition of orthologous proteins with pathogenic mutations (e.g., buff or carnation-like mutations)

• Epitope mapping: When using antibodies against mutant VPS33B, researchers should consider epitope mapping to ensure the mutation doesn't directly affect antibody binding

What is the stoichiometry of the VPS33B-VPS16B complex and how can antibody-based techniques help determine it?

The VPS33B-VPS16B complex has been determined to have an unusual stoichiometry, with two copies of VPS33B associated with three copies of VPS16B, forming a complex of approximately 315 kDa. Antibody-based techniques that can help determine this stoichiometry include:

• Quantitative immunoblotting: By using purified recombinant proteins as standards, researchers can quantify the relative amounts of VPS33B and VPS16B in immunoprecipitated complexes

• Blue native polyacrylamide gel electrophoresis (BN-PAGE): This technique preserves noncovalent interactions and can be combined with immunoblotting to determine complex size

• Antibody labeling for EM: By using antibodies conjugated to gold particles or other tags, researchers can visualize the number and arrangement of subunits in the complex via electron microscopy

• Cross-linking mass spectrometry: Chemical cross-linking followed by mass spectrometry with antibody-based enrichment can determine proximity and stoichiometry of complex components

BN-PAGE analysis of endogenous VPS33B-VPS16B complexes isolated from HEK293 and DAMI cells revealed they comigrate with the 480 kDa marker, significantly larger than the combined molecular weights of individual VPS33B (70.6 kDa) and VPS16B (57 kDa) proteins, supporting a multi-subunit complex .

How can researchers distinguish between direct and indirect effects of VPS33B antibodies in functional assays?

Distinguishing between direct and indirect effects of VPS33B antibodies in functional assays requires several control experiments:

• Specificity controls: Use pre-immune serum or irrelevant antibodies to control for non-specific effects

• Dose-response relationships: Test whether effects are proportional to antibody concentration

• F(ab) fragments: Use F(ab) fragments to eliminate potential Fc-mediated effects

• Rescue experiments: Attempt to rescue antibody-mediated inhibition with excess recombinant protein

• Comparative analysis with genetic approaches: Compare antibody inhibition phenotypes with those caused by genetic deletion or mutation of VPS33B

• Time-course experiments: Determine whether effects occur immediately (direct) or after a delay (indirect)

In cell-free assays, researchers demonstrated that antibodies against Vps33p inhibited transport by >90%, and this inhibition could be specifically rescued by adding cytosolic extracts from yeast cells overexpressing Vps33p, strongly suggesting a direct effect of the antibody on Vps33p function .

What methods are recommended for generating specific antibodies against VPS33B?

Based on successful previous approaches, the following methods are recommended for generating specific antibodies against VPS33B:

• Fusion protein expression: Express trpE-VPS33 fusion constructs in E. coli

• Insoluble fraction preparation: Isolate the insoluble fraction of cell lysates containing the fusion protein

• SDS-PAGE purification: Purify the fusion protein by SDS-PAGE and excise the band containing the protein

• Immunization: Use the gel slice containing the fusion protein as an antigen in rabbits

• Purification: Purify total IgG from immune sera using protein A-Sepharose columns

• Validation: Validate antibody specificity through Western blotting against recombinant VPS33B and immunoprecipitation experiments

This approach has successfully generated antibodies capable of >90% inhibition in transport assays, indicating high specificity and affinity for the target protein .

How should researchers optimize immunoprecipitation conditions for VPS33B-containing complexes?

Optimizing immunoprecipitation conditions for VPS33B-containing complexes requires careful consideration of several factors:

• Lysis buffer composition: Use buffers that preserve protein-protein interactions while efficiently lysing cells (e.g., TBST buffers with appropriate detergent concentrations)

• Cross-linking: Consider using DSP or other cross-linking agents to stabilize transient or weak interactions

• Recombinant tags: Express VPS33B with tags (e.g., HA) to facilitate efficient immunoprecipitation

• Salt concentration: Optimize salt concentration to minimize non-specific binding while maintaining specific interactions

• Incubation time and temperature: Adjust these parameters to maximize specific binding while minimizing degradation

• Washing conditions: Use stringent enough washing to remove non-specific binders without disrupting genuine interactions

Research has shown that using HA-tagged VPS33B and appropriate cross-linking can successfully co-precipitate interaction partners like VIPAS39/SPE-39 and HOPS complex components, allowing detailed analysis of how pathogenic mutations affect these interactions .

What are the recommended protocols for using VPS-33.1 antibodies in cell-free transport assays?

For using VPS-33.1 antibodies in cell-free transport assays, the following protocol is recommended based on published research:

• Membrane preparation:

  • Prepare donor membranes (125,000-g pellet enriched for radiolabeled proCPY)

  • Prepare acceptor membranes (15,000-g pellet enriched for vacuoles)

• Assay components:

  • Donor membranes (equivalent to 5 OD600 units of cells)

  • 100-125 μg of acceptor membranes

  • 1 mM ATP

  • 40 mM creatine phosphate

  • 0.2 mg/ml creatine kinase

  • 5 mg/ml cytosol

  • Total volume: 50 μl

• Antibody inhibition:

  • Pre-incubate components with anti-VPS33B antibodies at appropriate dilutions

  • Include pre-immune serum as a negative control

• Rescue experiments:

  • To confirm specificity, add cytosolic extracts from cells overexpressing VPS33B

• Incubation:

  • Assemble reactions on ice

  • Incubate at 25°C in a circulating water bath for 60 minutes

• Analysis:

  • Stop reactions with PMSF and denaturing buffer

  • Process samples for immunoprecipitation, SDS-PAGE, and autoradiography

This approach has been shown to provide a reliable cell-free system for studying VPS33B-dependent transport processes .

How should researchers interpret changes in VPS33B antibody binding patterns in mutant studies?

When interpreting changes in VPS33B antibody binding patterns in mutant studies, researchers should consider:

• Structural context: Analyze whether mutations are in domains directly involved in antibody binding or in regions that might indirectly affect conformation

• Correlation with function: Assess whether altered antibody binding correlates with functional defects or protein-protein interaction changes

• Conservation analysis: Consider whether mutations affect evolutionarily conserved regions, which may be particularly important for function

• Domain mapping: Use multiple antibodies targeting different epitopes to map which domains are affected by mutations

• Quantitative analysis: Perform quantitative immunoblotting to determine whether changes are complete or partial

Research has shown that mutations in the conserved region of VPS33B (amino acids 221-260) can have variable effects on protein interactions. For example, some mutations like the G249V (carnation-like) mutation disrupt VIPAS39/SPE-39 binding, while others like the ARC mutations D234H and S243F maintain this interaction despite causing disease phenotypes .

What statistical approaches are most appropriate for analyzing VPS33B antibody-based experiments?

For analyzing VPS33B antibody-based experiments, the following statistical approaches are recommended:

• For immunoprecipitation and binding studies:

  • Quantify band intensities from multiple independent experiments (n≥3)

  • Normalize to appropriate controls (input protein, wild-type binding)

  • Apply paired t-tests or ANOVA with appropriate post-hoc tests for comparing multiple conditions

  • Report results as mean ± standard deviation or standard error

• For transport inhibition assays:

  • Quantify the percentage of mature protein versus precursor forms

  • Compare inhibition across different antibody concentrations

  • Use dose-response curve analysis to determine IC50 values

  • Apply ANOVA or non-parametric alternatives for non-normally distributed data

• For microscopy-based colocalization studies:

  • Perform Pearson's or Mander's correlation coefficient analysis

  • Use appropriate thresholding methods

  • Apply statistical tests comparing correlation coefficients across conditions

• For protein complex analysis:

  • Use statistical approaches appropriate for the technique (MALS, SAXS, EM)

  • Report confidence intervals for measured parameters

  • Consider bootstrap or Monte Carlo approaches for complex data

How can researchers distinguish between antibody effects on VPS33B function versus expression?

To distinguish between antibody effects on VPS33B function versus expression, researchers should employ the following strategies:

• Western blot analysis: Compare VPS33B protein levels in antibody-treated versus control samples

• RT-qPCR: Assess VPS33B mRNA levels to determine whether antibody treatment affects transcription

• Pulse-chase experiments: Use metabolic labeling to determine protein synthesis and degradation rates

• Cell-free systems: Utilize in vitro assays where protein expression is not a factor

• Timing analyses: Examine the temporal relationship between antibody administration and observed effects

• Dose-response relationships: Test whether effects correlate with antibody concentration in a manner consistent with functional inhibition versus expression changes

Research using cell-free assays has demonstrated that anti-Vps33p antibodies can directly inhibit transport functions without affecting protein expression, as the assays use pre-formed proteins and membranes. This inhibition could be rescued by adding cytosolic extracts containing excess Vps33p, confirming a direct functional effect rather than an expression effect .

What emerging technologies could enhance the utility of VPS-33.1 antibodies in research?

Several emerging technologies could significantly enhance the utility of VPS-33.1 antibodies in research:

• Proximity labeling techniques: Combining VPS-33.1 antibodies with BioID or APEX2 proximity labeling systems could identify transient interaction partners or map the local protein environment

• Super-resolution microscopy: Techniques like STORM or PALM combined with highly specific antibodies could reveal nanoscale organization of VPS33B-containing complexes

• Cryo-electron microscopy: High-resolution structural analysis of antibody-labeled VPS33B complexes could provide detailed insights into complex assembly and conformation

• Single-molecule tracking: Using fluorescently labeled antibody fragments to track individual VPS33B molecules in living cells

• Optogenetic approaches: Combining antibody-based targeting with optogenetic tools to achieve temporally precise manipulation of VPS33B function

• CRISPR-based tagging: Endogenous tagging of VPS33B for improved antibody detection or alternative affinity purification approaches

These technologies could help address outstanding questions about the unique bidirectional structure of the VPS33B-VPS16B complex and its dynamic interactions during membrane fusion events .

How might VPS-33.1 antibodies contribute to understanding disease mechanisms in ARC syndrome?

VPS-33.1 antibodies could contribute significantly to understanding disease mechanisms in ARC syndrome through several research approaches:

• Epitope-specific antibodies: Developing antibodies that specifically recognize wild-type versus mutant forms of VPS33B could help track protein localization and complex formation in patient-derived cells

• Structure-function studies: Using antibodies to probe conformational changes in VPS33B caused by disease-associated mutations

• Therapeutic development: Screening for antibodies that might stabilize mutant VPS33B-VIPAS39 interactions as potential therapeutic agents

• Biomarker development: Using antibodies to detect aberrant VPS33B complex formation or localization as diagnostic or prognostic biomarkers

• Phenotypic rescue experiments: Determining whether cell-permeable antibodies could rescue certain cellular phenotypes in patient-derived cells

• Interaction partner mapping: Comprehensive immunoprecipitation studies to identify how disease mutations alter the VPS33B interactome

Research has shown that pathogenic mutations in VPS33B have variable effects on interactions with VIPAS39/SPE-39. For example, the L30P mutation disrupts this interaction, while other mutations like D234H maintain binding despite causing disease. This suggests multiple mechanisms by which mutations can lead to ARC syndrome, which could be further explored using antibody-based approaches .

How do yeast two-hybrid versus immunoprecipitation methods compare for studying VPS33B interactions?

When studying VPS33B interactions, yeast two-hybrid (Y2H) and immunoprecipitation (IP) methods offer complementary strengths and limitations:

Research on VPS33B has successfully used both approaches in complementary ways. Y2H demonstrated that VIPAS39/SPE-39 directly binds to Vps33b but not to Vps11 or Vps18, favoring a model where VIPAS39/SPE-39 associates with the class C core complex through Vps33b. These Y2H results were validated by immunoprecipitation experiments in mammalian cells, showing the value of using both techniques .

What are the relative advantages of polyclonal versus monoclonal antibodies for VPS33B research?

Polyclonal and monoclonal antibodies each offer distinct advantages for VPS33B research:

How do native versus denaturing conditions affect VPS-33.1 antibody performance in different applications?

The choice between native and denaturing conditions significantly impacts VPS-33.1 antibody performance across different applications:

Research on VPS33B-VPS16B complexes has utilized both approaches strategically. Blue native PAGE combined with immunoblotting preserved the native complex structure, revealing that VPS33B-VPS16B forms a high molecular weight complex of approximately 480 kDa in HEK293 and DAMI cells. For binding studies, both native conditions (for co-immunoprecipitation of intact complexes) and denaturing conditions (for Western blot detection) were used in complementary fashion .